Optaflu
Optaflu is a cell culture derived influenza vaccine manufactured by Novartis.
Influenza (Flu) |
---|
Types |
|
Vaccines |
|
Treatment |
Pandemics |
|
Outbreaks |
|
See also |
|
History
On April 27, 2007 Novartis received a positive opinion supporting European Union approval of Optaflu. It is the first influenza vaccine made in a mammalian cell line, rather than chicken eggs.[1] The vaccine will be manufactured in Holly Springs, North Carolina. The United States government is providing $500 million in construction costs and guaranteed vaccine purchases.[2]
References
- "Optaflu, the Novartis cell culture-derived influenza vaccine, receives positive opinion supporting European Union regulatory approval". Novartis. Retrieved 2009-04-29.
- Pollack, Andrew (2009). "Swine Flu Vaccine May Be Months Away, Experts Say". New York Times. Retrieved 2009-04-29.
But Novartis is building a cell culture flu vaccine factory in Holly Springs, N.C., which might be ready for use in 2010 or 2011. The federal government is providing nearly $500 million in construction costs and guaranteed vaccine purchases.
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.